European pharma just found its growth engine. It’s not in Europe. Bain quantified what the smartest European mid-sized pharma companies have been executing. 𝟴% 𝗖𝗔𝗚𝗥 𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗹𝗮𝘀𝘁 𝗱…
LinkedIn Content Strategy & Writing Style
Unknown
1 person tracking this creator on Viral Brain
This creator positions themselves as a strategic bridge between clinical science and commercial finance, operating as a high-level analyst for the life sciences sector. Their content strategy centers on deconstructing complex market shifts—such as the rise of royalty financing and the geographic pivot of European mid-pharma—into actionable insights for biotech founders and investors. They are notable for their ability to humanize corporate transitions, using cultural touchpoints like Olympic sharpshooters to explain the divergent skill sets of drug discovery versus commercial execution. By intersecting macroeconomic data with organizational psychology, they provide a sophisticated value proposition that helps stakeholders navigate the "industrialization" of biotech beyond the laboratory.
—
—
European pharma just found its growth engine. It’s not in Europe. Bain quantified what the smartest European mid-sized pharma companies have been executing. 𝟴% 𝗖𝗔𝗚𝗥 𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗹𝗮𝘀𝘁 𝗱…
Nail your LinkedIn strategy with ViralBrain.
Analyze and write in Unknown's style. Grow your LinkedIn to the next level.
—
—
—
—
0
Uğur Şahin and Özlem Türeci just announced they're leaving BioNTech. Am I the only one getting Yusuf Dikeç vibes from this? The founders' scientific ambitions no longer fit perfectly with the day-to-…
𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗘𝗾𝘂𝗶𝘁𝘆 is becoming Pharma’s New Co-Developers via 𝗿𝗼𝘆𝗮𝗹𝘁𝘆 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗻𝗴. This 𝗶𝘀𝗻’𝘁 𝘃𝗲𝗻𝘁𝘂𝗿𝗲 𝗰𝗮𝗽𝗶𝘁𝗮𝗹. This 𝗶𝘀𝗻’𝘁 𝗮 𝗹𝗶𝗰𝗲𝗻𝘀𝗶𝗻𝗴 𝗱𝗲𝗮𝗹. T…
UK drug maker AstraZeneca’s CEO warns Europe on missing on new drugs and turning into a mere sales office for the industry. Pascal Soriot warned this week that Germany's plans to cut pharmaceutical s…
Pharma's urgency to replenish its P&Ls has created a void in the market. Nature hates a vacuum. Enter new buyers. Biotechs with rare disease assets under $1-2B USD peak revenue have faced a dead end—…
European pharma just found its growth engine. It’s not in Europe. Bain quantified what the smartest European mid-sized pharma companies have been executing. 𝟴% 𝗖𝗔𝗚𝗥 𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗹𝗮𝘀𝘁 𝗱…